Press release
Natural Killer NK Cell Lymphoma Pipeline Expands with 100+ Companies Leading Innovation - DelveInsight | NantKwest, Green Cross Corporation, HiberCell, Bristol-Myers Squibb, Innate Pharma, Affimed Therapeutics AG, Wugen
Natural Killer NK Cell Lymphoma Pipeline
DelveInsight's "Natural Killer NK Cell Lymphoma Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Natural Killer NK Cell Lymphoma market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.
For emerging Natural Killer NK Cell Lymphoma drugs, the Natural Killer NK Cell Lymphoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Natural Killer NK Cell Lymphoma Pipeline Report
• DelveInsight's Natural Killer NK Cell Lymphoma Pipeline analysis depicts a robust space with 100+ active players working to develop 140+ pipeline drugs for Natural Killer NK Cell Lymphoma treatment.
• The leading Natural Killer NK Cell Lymphoma companies include ImmunityBio, Five Prime Therapeutics, Innate Pharma, Nektar Therapeutics, Cantargia, CureTech, Dynavax, Cellid Company, Kiadis Pharma, Multimmune GmbH, CytoVac, XNK Therapeutics, NantKwest, Green Cross Corporation, HiberCell, Bristol-Myers Squibb, Innate Pharma, Affimed Therapeutics AG, Wugen, Abivax, Glycostem Therapeutics (IPD Therapeutic), Synimmune, GT Biopharma, Bellicum Pharmaceuticals, Asclepius Technology Company Group, PersonGen BioTherapeutics (Suzhou), Chongqing Sidemu Biotechnology, Artiva Biotherapeutics, NKMax, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, Kuur Therapeutics (Formerly Cell Medica), and others are evaluating their lead assets to improve the Natural Killer NK Cell Lymphoma treatment landscape.
• Key Natural Killer NK Cell Lymphoma pipeline therapies in various stages of development include ALT 803, Bemarituzumab, Monalizumab, NKTR-214 (Bempegaldesleukin), Nidanilimab, Pidilizumab, SD-101, BVAC-C, PD-L1.t-haNK, K-NK002, Enkastim, ALECSAT, CellProtect, Nk-92, haNk, MG4101, Imprime PGG, Lirilumab, IPH4102, AFM-13, WU-NK-101, ABX196, AFM24, PNK-007, Allogeneic Natural Killer Cell Therapy (oNKord), FLYSYN, KNK-ID-101, GTB-3550, CAR-NK cells, DF1001, DF-6002, NKG2D-ACE2 CAR-NK Cells, AB-101, SNK01, NKTR-225, and others.
• In August 2024, Indapta Therapeutics received FDA IND clearance for its Phase 1 trial of IDP-023, a g-NK cell therapy for progressive multiple sclerosis.
• In June 2024, GT Biopharma secured FDA IND clearance to initiate a Phase 1 trial of GTB-3650 for CD33+ leukemia.
• In May 2024, the FDA granted orphan drug designation to IGNK001 (Gengleucel) for the treatment of acute myeloid leukemia (AML).
• In April 2024, the FDA also granted orphan drug designation to IGNK001 (Gengleucel) for AML.
Request a sample and discover the recent breakthroughs happening in the Natural Killer NK Cell Lymphoma pipeline landscape @ https://www.delveinsight.com/report-store/natural-killer-nk-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Natural Killer NK Cell Lymphoma Overview
Natural killer cells, also known as NK cells, are a type of lymphocytes and are key components of the innate immune system. They are highly specific predators that play a major role in the host rejection of both tumors and virus-infected cells. NK cell abnormalities have been observed in several cancer patients, including decreased cytotoxicity, defective expression of activating receptors or intracellular signaling molecules, overexpression of inhibitory receptors, defective proliferation, and decreased numbers in peripheral blood and tumor infiltrate, and defective cytokine production.
NK cell therapy has been most successful in hematopoietic malignancies, such as leukemias. NK cell immunotherapy can be achieved by either activating endogenous NK cell response by administering NK stimulants or using exogenous NK cells via HSCT or adoptive cell transfer. Several strategies for NK cell immunotherapies for human cancer have been proposed to date. NK cell immunotherapy can be achieved in several ways.
Find out more about Natural Killer NK Cell Lymphoma medication @ https://www.delveinsight.com/report-store/natural-killer-nk-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Natural Killer NK Cell Lymphoma Treatment Analysis: Drug Profile
Monalizumab: Innate Pharma
Monalizumab (IPH2201) is a first-in-class humanized IgG4 antibody that targets NKG2A receptors on tumor-infiltrating cytotoxic NK and CD8 T cells. Developed by Innate Pharma, it is currently in Phase III trials for Squamous Cell Carcinoma of the Head and Neck and Phase II for gynecological cancers, chronic lymphocytic leukemia, and head and neck cancer. Additionally, it is in Phase I trials for advanced solid tumors and hematologic malignancies.
NKTR-214 (Bempegaldesleukin): Nektar Therapeutics
NKTR-214 is designed to enhance the body's cancer-fighting immune response by expanding tumor-infiltrating lymphocytes (TILs), including cancer-killing T cells and NK cells. It works by targeting CD122-specific receptors on CD8+ effector T cells and NK cells, which are crucial for immune cell proliferation. CD122, also known as the Interleukin-2 receptor beta subunit, plays a key role in boosting these immune responses.
Key Natural Killer NK Cell Lymphoma Therapies and Companies
• Monalizumab: Innate Pharma
• NKTR-214 (Bempegaldesleukin): Nektar Therapeutics
• ALT 803: ImmunityBio
• ALECSAT: CytoVac
• PNK-007: Celularity
Learn more about the novel and emerging Natural Killer NK Cell Lymphoma pipeline therapies @ https://www.delveinsight.com/report-store/natural-killer-nk-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Natural Killer NK Cell Lymphoma Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Intracranial
• Intramuscular
• Intratumoral
• Intravenous
• Intravenous
• Parenteral
• Subcutaneous
By Molecule Type
• Small molecule
• Antibodies
• Beta Glucans
• CAR-NK cell therapy
• Cell Therapy
• Gene therapies
• Glycolipid
• NK Cell therapy
• NK T-Cell therapy
• Oligodeoxyribonucleotides
• Proteins
• RNA
• Stem cell therapies
• Vaccines
Scope of the Natural Killer NK Cell Lymphoma Pipeline Report
• Coverage: Global
• Key Natural Killer NK Cell Lymphoma Companies:ImmunityBio, Five Prime Therapeutics, Innate Pharma, Nektar Therapeutics, Cantargia, CureTech, Dynavax, Cellid Company, Kiadis Pharma, Multimmune GmbH, CytoVac, XNK Therapeutics, NantKwest, Green Cross Corporation, HiberCell, Bristol-Myers Squibb, Innate Pharma, Affimed Therapeutics AG, Wugen, Abivax, Glycostem Therapeutics (IPD Therapeutic), Synimmune, GT Biopharma, Bellicum Pharmaceuticals, Asclepius Technology Company Group, PersonGen BioTherapeutics (Suzhou), Chongqing Sidemu Biotechnology, Artiva Biotherapeutics, NKMax, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, Kuur Therapeutics (Formerly Cell Medica), and others.
• Key Natural Killer NK Cell Lymphoma Pipeline Therapies: ALT 803, Bemarituzumab, Monalizumab, NKTR-214 (Bempegaldesleukin), Nidanilimab, Pidilizumab, SD-101, BVAC-C, PD-L1.t-haNK, K-NK002, Enkastim, ALECSAT, CellProtect, Nk-92, haNk, MG4101, Imprime PGG, Lirilumab, IPH4102, AFM-13, WU-NK-101, ABX196, AFM24, PNK-007, Allogeneic Natural Killer Cell Therapy (oNKord), FLYSYN, KNK-ID-101, GTB-3550, CAR-NK cells, DF1001, DF-6002, NKG2D-ACE2 CAR-NK Cells, AB-101, SNK01, NKTR-225, and others.
Dive deep into rich insights for drugs used for Natural Killer NK Cell Lymphoma treatment; visit @ https://www.delveinsight.com/report-store/natural-killer-nk-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Natural Killer NK Cell Lymphoma Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Natural Killer NK Cell Lymphoma Pipeline Therapeutics
6. Natural Killer NK Cell Lymphoma Pipeline: Late-Stage Products (Phase III)
7. Natural Killer NK Cell Lymphoma Pipeline: Late-Stage Products (Phase III)
8. Natural Killer NK Cell Lymphoma Pipeline: Mid-Stage Products (Phase II)
9. Natural Killer NK Cell Lymphoma Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Natural Killer NK Cell Lymphoma Pipeline Expands with 100+ Companies Leading Innovation - DelveInsight | NantKwest, Green Cross Corporation, HiberCell, Bristol-Myers Squibb, Innate Pharma, Affimed Therapeutics AG, Wugen here
News-ID: 3942900 • Views: …
More Releases from DelveInsight
Type 2 Diabetes Pipeline Insight 2025: Next-Gen Incretins, Gene Therapies, and M …
DelveInsight's "Type 2 Diabetes - Pipeline Insight, 2025" explores the evolving pipeline for type 2 diabetes (T2D), a chronic disorder marked by insulin resistance and progressive β-cell dysfunction. Despite widely used options like metformin, SGLT2 inhibitors, GLP-1 receptor agonists, and insulin, the global burden of T2D continues to rise, creating demand for therapies that go beyond glucose control to address weight, cardiovascular risk, and long-term disease modification.
The pipeline is advancing…
Wet Age-Related Macular Degeneration Pipeline Insight 2025: Over 60+ Companies A …
DelveInsight's "Wet-AMD - Pipeline Insight, 2025" maps a fast-moving landscape for neovascular (wet) age-related macular degeneration, a leading cause of vision loss driven by choroidal neovascularization and exudation. Today's standard of care relies on frequent intravitreal anti-VEGF injections, which are highly effective but create a heavy treatment burden and adherence challenges.
The pipeline is shifting toward durability and disease modification. Next-gen biologics (long-acting antibodies, bispecifics, and high-affinity fragments), small-molecule TKIs in…
Pulmonary Embolism Pipeline Insight 2025: Novel Anticoagulants, Thrombolytics, a …
DelveInsight's "Pulmonary Embolism - Pipeline Insight, 2025" explores the advancing treatment landscape for pulmonary embolism, a life-threatening condition resulting from obstruction of the pulmonary arteries, most often due to venous thromboembolism. Current management primarily relies on anticoagulation with heparins, vitamin K antagonists, or direct oral anticoagulants, and in severe cases, systemic thrombolysis or catheter-directed interventions. While these approaches improve survival, they are limited by bleeding risks, suboptimal clot resolution, and…
Immune Thrombocytopenia Clinical Trials 2025: Advancing TPO-R Agonists, FcRn Blo …
DelveInsight's "Immune Thrombocytopenia (ITP) - Pipeline Insight, 2025" highlights the rapidly evolving therapeutic landscape for ITP, an autoimmune bleeding disorder characterized by accelerated platelet destruction and impaired platelet production. Current treatments, such as corticosteroids, intravenous immunoglobulin (IVIG), rituximab, and thrombopoietin receptor (TPO-R) agonists like eltrombopag and romiplostim, provide effective short-term control for many patients, but relapses, refractoriness, and treatment-related toxicity remain significant challenges.
The pipeline is shifting toward therapies that deliver…
More Releases for Cell
Cell Isolation Cell Separation Market Size Analysis by Application, Type, and Re …
According to Market Research Intellect, the global Cell Isolation Cell Separation market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period.
The market for cell isolation and separation is expanding rapidly as a result of sophisticated biotechnological…
Cell Free Protein Synthesis Market Beyond the Cell: Revolutionizing Protein Prod …
Cell-Free Protein Synthesis Market to reach over USD 457.13 Mn by the year 2031 - Exclusive Report by InsightAce Analytic
"Cell-Free Protein Synthesis Market" in terms of revenue was estimated to be worth $265.94 Mn in 2023 and is poised to reach $457.13 Mn by 2031, growing at a CAGR of 7.20% from 2024 to 2031 according to a new report by InsightAce Analytic.
Request for free Sample Pages: https://www.insightaceanalytic.com/request-sample/1445
Current…
Cell Expansion Market - Expand the Boundaries of Cell Therapy: Redefine Cell Exp …
Newark, New Castle, USA: The "Cell Expansion Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Cell Expansion Market: https://www.growthplusreports.com/report/cell-expansion-market/7939
This latest report researches the industry structure, sales, revenue,…
Global GMP Cell Banking Market By Type - Mammalian Cell, Microbial Cell, Insect …
Researchmoz added Most up-to-date research on "Global GMP Cell Banking Market By Type - Mammalian Cell, Microbial Cell, Insect Cell and Others" to its huge collection of research reports.
This report researches the worldwide GMP Cell Banking market size (value, capacity, production and consumption) in key regions like North America, Europe, Asia Pacific (China, Japan) and other regions.
This study categorizes the global GMP Cell Banking breakdown data by manufacturers, region, type…
Cell Culture Market Size, Cell Culture Market Share, Cell Culture Market Trends …
According to a new research published by Polaris Market Research the global cell culture market is anticipated to reach more than USD 49 billion by 2026. Cell culture is a rapidly emerging as an implement for analyzing and treating various disease such as Alzheimer’s and cancer.
Request for Sample of This Research Report @ https://bit.ly/2D7pZ5u
Top Key Players: -
Becton,
Dickinson and Company
Biospherix
EMD Millipore
Eppendorf AG
Merck KGaA
Sartorius AG
VWR International
Cell culture is a rapidly emerging…
Cell Banking Outsourcing Market Report 2018: Segmentation by Type of Bank (Maste …
Global Cell Banking Outsourcing market research report provides company profile for Charles River Laboratories, Cryo-Cell International Inc., BioOutsource (Part of Sartorious Stedim Biotech Group)Ltd., BioReliance Corporation, BSL Bioservice Scientific Laboratories Munich GmbH, Cleancells, CordLife Group Ltd and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY…
